Traditional Chinese medicine enema for acute chronic liver failure
A protocol of systematic review and meta-analysis of randomized clinical trials
Yueqiao Chen, MD\textsuperscript{a,b}, Yehao Luo, MS\textsuperscript{a}, Fenglan Wu, MS\textsuperscript{a}, Nansheng Liao, MS\textsuperscript{a}, Qinglan Shi\textsuperscript{b}, Dewen Mao\textsuperscript{b,∗}

Abstract
Background: Acute chronic liver failure (ACLF) is the most common type of liver failure. The clinical symptoms are complex and changeable, the treatment is difficult and the fatality rate is high. It has become an urgent problem to actively seek effective treatment means and improve the clinical efficacy of ACLF patients. Studies have shown that decreased intestinal barrier function and bacterial endotoxin translocation in ACLF patients are considered to be the key causes of enterogenic endotoxemia, and traditional Chinese medicine enema has certain advantages in adjuvant treatment of this disease. However, due to the lack of evidence, there is no specific method or suggestion, so it is necessary to carry out systematic evaluation on Traditional Chinese medicine enema for ACLF and provide effective evidence for further research.

Methods: We will search the following electronic databases from their inception to July 2020: Electronic database includes PubMed, Embase, Cochrane Library, Chinese Biomedical Database WangFang, VIP medicine information, and China National Knowledge Infrastructure. Primary outcomes: survival rates, TCM syndrome score. Secondary outcomes: liver function (alanine aminotransferase, aspartic acid amino transferase, total bilirubin), blood coagulation function (prothrombin activity), adverse events. Data will be extracted by 2 researchers independently, risk of bias of the meta-analysis will be evaluated based on the Cochrane Handbook for Systematic Reviews of Interventions. All data analysis will be conducted by data statistics software Review Manager V.5.3. and Stata V.12.0.

Results: The results of this study will systematically evaluate the effectiveness and safety of Traditional Chinese medicine enema for ACLF.

Conclusion: The systematic review of this study will summarize the currently published evidence of Traditional Chinese medicine enema for ACLF to further guide its promotion and application.

Abbreviations: ACLF = acute chronic liver failure, RCT = randomized controlled trial.

Keywords: acute chronic liver failure, enema, meta-analysis and systematic review, protocol, traditional Chinese medicine

1. Introduction
Acute chronic liver failure (ACLF) is based on chronic liver disease, acute decompensation and liver failure occurred in a short period of time.\textsuperscript{[1]} Liver failure caused by hepatitis B virus (HBV) is the most common, in which ACLF as the main clinical manifestation, accounting for 80\% to 90\% in China.\textsuperscript{[2]} It has high fatality rate, many complications, and great difficulty in treatment.\textsuperscript{[3,4]} Generally, there is no particularly effective
treatment for patients with ACLF, and liver transplantation is the ultimate effective treatment. However, the disease control effect after standardized treatment by western medicine is poor, which is difficult to meet the clinical needs. In recent years, Traditional Chinese medicine enema has been widely used in clinical and experimental studies of ACLF, it has been shown to have some advantages in protecting liver function and delaying disease progression. As a form of Chinese medicine adjuvant therapy, the traditional Chinese medicine enema has been used to improve symptoms in ACLF patients, but its effectiveness and safety have not yet reached a definitive conclusion. Therefore, this research intends to adopt the method of system evaluation and meta-analysis of the traditional Chinese medicine enema for ACLF to evaluate the efficacy and safety.

2. Methods

2.1. Study registration

The protocol of the systematic review has been registered.

Registration: OSF Preregistration 29 August, 2020. https://osf.io/8xazf. This systematic review protocol will be conducted and reported strictly according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement guidelines, and the important protocol amendments will be documented in the full review.

2.2. Inclusion and exclusion criteria for study selection

2.2.1. Inclusion criteria. Inclusion criteria are all randomized controlled trials (RCTs), which main treatment of ACLF is traditional Chinese medicine enema or Traditional Chinese medicine enema with oral Chinese medicine decoction. The language of the trials to be included only Chinese or English.

2.2.2. Exclusion criteria. Following studies will be excluded

1. Repeated publications
2. Review of literature and cases
3. Animal studies
4. Incomplete literature
5. Non-RCTs

2.3. Types of participants

The types of subjects included patients diagnosed with HBV-ACLF, regardless of their degree and possible complications. All patients were treated with traditional Chinese medicine enema or Traditional Chinese medicine enema with oral Chinese medicine decoction. Due to the different pathogenesis and mechanism, we will exclude patients with HAV, HCV, HDV, HEV, and HIV infection, hepatocellular carcinoma, or those who had undergone surgery, and those who had previously received antiviral therapy with nucleoside (acid) analogs.

2.4. Interventions and controls

Interventions included treatment with traditional Chinese medicine enema or Traditional Chinese medicine enema with oral Chinese medicine decoction. The control group only received conventional western medicine treatment. The routine treatment of each RCT may not be identical, but the use of Traditional Chinese medicine enema or Traditional Chinese medicine enema with oral Chinese medicine decoction is the only difference between intervention and control.

2.5. Types of outcome measures

2.5.1. Main outcomes.

1. Survival rates;
2. TCM syndrome score

2.5.2. Additional outcomes.

1. Alanine aminotransferase;
2. Aspartic acid amino transferase;
3. Total bilirubin;
4. Prothrombin activity.

2.6. Search methods

2.6.1. Search resources. We will search the following electronic databases from their inception to July 2020: Electronic database includes PubMed, Embase, Cochrane Library, Chinese Biomedical Database WangFang, VIP medicine information, and China National Knowledge Infrastructure. (Fig. 1) The research flowchart.

2.6.2. Search strategies. The following MeSH terms and their combinations will be searched:

(1) Traditional Chinese medicine enema or Traditional Chinese medicine enema with oral Chinese medicine decoction;
(2) RCT OR RCTs;
(3) Acute Chronic Liver Failure.

The search strategy for PubMed is shown in (Table 1). Other electronic databases will be used in the same strategy.

2.7. Data collection and analysis

2.7.1. Studies selection. There will be 2 researchers (YC and FW) carry out the selection of research literature independently using NoteExpress software. We will first make the preliminary selection by screening titles and abstracts. Second, we will download full text of the relevant studies for further selection according to the inclusion criteria. If there is any different opinion, 2 researchers will discuss and reach an agreement. If a consensus could not be reached, there will be a third researcher (QS) who make the final decision. The details of selection process will be displayed in the Preferred Reporting Items for Systematic Reviews and Meta-Analyses flow chart.

2.7.2. Data extraction. Two researchers (NL and YL) will read all the included text in full, and independently extract the following information:

(1) General information, including trial name and registration information;
(2) Trial characteristic, including trial design, location, setting, and inclusion/exclusion criteria;
(3) The characteristics of the participants, including age, race/ethnicity, course of illness, and so on.
(4) Details of intervention, including acupoints, time of intervention, course of treatment, time of single treatment, and so on;
(5) Details of comparison interventions;
(6) Outcomes as described under type of outcome measure section.
If we could not reach an agreement, a third researcher (DM) would make the final decision. One researcher (YC) would contact the corresponding author by telephone or e-mail for more information when the reported data were insufficient or ambiguous.

2.7.3. Assesment of risk of bias. All the included studies will be evaluated based on the guidelines of Cochrane Handbook for Systematic Reviews of Interventions. The quality of each trial will categorized into “low,” “unclear,” or “high” risk of bias according to the following items: adequacy of generation of the allocation sequence, allocation concealment, blinding of participants and personal, blinding of outcome assessors, incomplete outcome data, selected reporting the results and other sources of bias (such as comparable baseline characteristic, inclusion and exclusion criteria).

2.7.4. Assessment of reporting biases. Reporting biases and small-study effects will be detected by funnel plot and Egger test if there are 10 more studies included in this Meta-analysis. For
Egger test, $P$-value of $<.10$ was considered to indicate the exist of reporting biases and small study effects.

2.7.5. Data analysis. We used Revman 5.3 software provided by the Cochrane collaboration to analyze the data. Binary outcomes will be summarized using risk ratio with 95% confidence interval for relative effect. Continuous outcomes will be summarized by using weighted mean difference with 95% confidence interval. We will use random-effect model for meta-analysis in this review according to research recommendations.[10]

Statistical heterogeneity will be assessed by $X^2$ and $I^2$ statistical tests. Where $P$-value $\geq .1$ and $I^2 \leq 50\%$, there is no obvious statistical heterogeneity among the studies. On the contrary, where $P$-value $<.1$ or $I^2 > 50\%$ indicates a considerable heterogeneity. Meta-analysis will be performed when the statistical heterogeneity is acceptable ($P$-value $\geq .1$ and $I^2 \leq 50\%$), otherwise, subgroup analysis will be applied to explore the influence of potential factors on the outcome measures. We will conduct sensitivity analyses by omitting studies one by one in order to probe the impact of an individual study. If a meta-analysis cannot be performed, we will conduct descriptive analysis instead.

2.7.6. Patient and public involvement. This is a meta-analysis study based on previously published data, so patient and public involvement will not be included in this study.

2.7.7. Ethics and dissemination. Ethical approval will not be required as this is a protocol for systematic review and meta-analysis. The findings of this study will be disseminated to a peer-reviewed journal and presented at a relevant conference.

2.7.8. Evidence assessed. The quality of evidence for this study will be assessed by “Grades of Recommendations Assessment, Development, and Evaluation (GRADE)” standard established by the World Health Organization and international organizations.[11] To achieve transparency and simplification, the quality of evidence is divided into 4 levels in GRADE system: high, medium, low, and very low. We will employ GRADE profiler 3.2 for analysis.[12]

3. Discussion

ACLF has always been one of the key and difficult points in medical research, because of its high morbidity and mortality. The most common hepatitis B-related ACLF in China is caused by HBV infection.[13] The patient has a long history of basic hepatitis B, and the liver cells are constantly damaged, which induces a large number of pathogenic factors accumulation and internal environment disorder. It leads to a large number of hepatocyte apoptosis. The survival number, regeneration ability, and environment of hepatocytes determine whether the patients can survive or not.[14,15] The main causes of liver injury in the West are alcohol intake, infection and so on, which is mainly alcoholic liver disease.[16] The current treatment focuses on protecting living hepatocytes, promoting their regeneration, and improving the cellular environment.[17]

However, these are not enough to reduce the mortality of ACLF. Although artificial liver and liver transplantation are now become the most effective treatment methods, the problems such as high cost, liver source scarcity and patient rejection have not been solved. Therefore, these 2 most effective methods have not been carried out in all patients.[18,19] A growing body of research have shown that TCM enema can improve the clinical efficacy and quality of life of HBV-ACLF patients. Intestinal endotoxemia is the main pathogenesis of hepatocyte necrosis, so that reducing intestinal endotoxemia and avoiding intestinal infection is the key to the treatment of the disease.[20,21] Traditional Chinese medicine enema can prevent the production and absorption of intestinal toxins, accelerate the metabolism of intestinal toxins, reduce the occurrence and development of intestinal endotoxemia, so as to slow down the symptoms of HE and enhance patients’ immunity and other unique functions and advantages.

Author contributions

Conceptualization: Yueqiao Chen.
Data curation: Yueqiao Chen, Yehao Luo.
Formal analysis: Yehao Luo, Qinglan Shi.
Funding acquisition: Dewen Mao.
Investigation: Nansheng Liao.
Methodology: Nansheng Liao.
Project administration: Dewen Mao.
Resources: Fenglan Wu.
Software: Fenglan Wu.
Supervision: Dewen Mao.
Writing – original draft: Yueqiao Chen, Yehao Luo.
Writing – review & editing: Dewen Mao.

References

[1] Liver Failure and Artificial Liver Group, Chinese Society of Infectious Diseases, and Severe Liver Disease and Artificial Liver Group, Chinese Society of HepatopathyGuidelines for the diagnosis and treatment of liver failure (2018 edition). Chin J Hepatol 2019;27:18-26.
[2] Liver Failure and Artificial Liver Treatment Group, Chinese Association of Infectious Diseases, Chinese Medical Association, heavy liver and artificial liver groupGuidelines for diagnosis and treatment of liver failure. Chin J Hepatol 2006;14:634-6.
[3] Liver Failure and Artificial Liver Group, Chinese Society of Infectious Diseases, and Severe Liver Disease and Artificial Liver Group, Chinese Society of HepatopathyGuidelines for the diagnosis and treatment of liver failure (2012 edition). J Pract Hepatol 2013;16:210-6.
[4] Kabbami AR, Tergast TL, Manners MP, et al. Behandlungsstrategien des akut-auf-chronischen Leberversagens [treatment strategies for acute-on-chronic liver failure] [published online ahead of print, 2019 Aug 23]. Med Klin Intensivmed Notfmed 2019;1:3. doi:10.1007/s00063-019-00613-x.
[5] Chunyan L. Clinical Characteristics and Prognostic Analysis of 296 Cases of Chronic Acute Liver Failure. 2018JKlin University.
[6] Gao FY, Sun L, Ye XQ, et al. Development and validation of a prognostic model for acute-on-chronic hepatitis B liver failure. Eur J Gastroenterol Hepatol 2017;29:669-78.
Huimin L, Fangyuan G, Yuyong J, et al. Clinical observation of 30 cases of chronic hepatitis B plus acute liver failure treated with detoxification, blood-cooling and Wet-removing prescription combined with Western medicine. J Tradit Chin Med 2016;59:41–5.

Shamseer L, Moher D, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ 2015;349:g7647–7647.

Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0: The Cochrane Collaboration, 2011. Available at: http://www.equator-network.org/reporting-guidelines/cochrane-handbook-for-systematic-reviews-of-interventions-version-5-1-0/.

Furlan AD, Pennick V, Bombardier C, et al. 2009 updated method guidelines for systematic reviews in the Cochrane Back Review Group. Spine 2009;34:1929–41.

Balsam H, Helfand M, Schunemann HJ, et al. GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol 2001;64:401–6.

Schunemann H, Brozek J, Guyatt G, Oxman A, editor(s). Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach (updated October 2013). GRADE Working Group, 2013. Available at: http://gdt.guidelinedevelopment.org/app/.

Liu Hong, Chen Gang, GAN Xuemei. New technology and research progress in the treatment of chronic acute liver failure. J Clin Hepatobil Dis 2015;31:1496–500.

Bernal W, Jalan R, Quaglia A, et al. Acute-on-chronic liver failure. Lancet 2015;386:1576–87.

Li H, Zheng J, Chen L, et al. The scoring systems in predicting short-term outcomes in patients with hepatitis B virus-related acute-on-chronic liver failure. Ann Palliat Med 2020.

Marot A, Singal AK, Moreno C, et al. Granulocyte colony-stimulating factor for alcoholic hepatitis: a systematic review and meta-analysis of randomised controlled trials. JHEP Rep 2020;2:100139.

Guo X, Wu F, Guo W, et al. Comparison of plasma exchange, double plasma molecular adsorption system, and their combination in treating acute-on-chronic liver failure. J Int Med Res 2020;48:300060520932053.

Yang L, Wu T, Li J, et al. Artificial liver treatment improves survival in patients with hepatitis B virus-related acute-on-chronic liver failure: a case-control matched analysis. Hepatol Res 2020;50:656–70.

Zhang X, Ying Y, Zhou P, et al. A stepwise evaluation of hepatitis B virus-related acute-on-chronic liver failure to optimize the indication for urgent liver transplantation. Dig Dis Sci 2020;doi:10.1007/s10620-020-06149-x.

Tam L, Karvellas C, Sy E. The use of high volume plasmapheresis in acute liver failure. Cureus 2020;12:e8721.

Zhengrong T, Yongjun X, Qing Z, et al. Effect observation of Qudu Huchang Decoction enema with western medicine in the treatment of HBV associated chronic plus acute liver failure enterogenous endotoxemia. Chin Med Emerg 2008;27:2217–9.